Phase 1Recruiting

Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance. (UPGRADE)

Alpha to Beta Cell Communication in Health and Disease

Sponsor
David D'Alessio, M.D. (Academic or other)
Enrolment
30 planned
Conditions
Diabetes (DM)
Interventions
Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min; Dexamethasone; Dextrose 20% solution; Dextrose 20% solution
Ages
adults
Registry
NCT07224334

From the registry

Glucagon secretion from α-cells has long been viewed as primarily a counterregulatory mechanism - e.g. an agent with a role to prevent blood sugar from decreasing to levels that compromise function. Our group, along with other researchers, have begun to identify a much more complex role for α-cells, raising questions about when and how glucagon may influence blood glucose levels. This proposal looks to detail proglucagon peptide secretion from α-cells and the impact this has on β-cell function and glucose tolerance, in preclinical studies of human islets and translational studies in human subjects. This protocol registration describes Aim 2 from this NIH grant which involves 2 study populations and separate protocols but addresses a common question. Aim 3 in the grant is focused on a separate hypothesis and will be conducted and published separately from Aim 2.

Primary outcomes

  • Insulin secretion with and without exendin-9: Aims 2A and 2B
Full record on ClinicalTrials.gov